Effects of rye and whole wheat versus refined cereal foods on metabolic risk factors: a randomised controlled two-centre intervention study. by Giacco, Rosalba et al.
at SciVerse ScienceDirect
Clinical Nutrition 32 (2013) 941e949Contents lists availableClinical Nutrition
journal homepage: ht tp: / /www.elsevier .com/locate/c lnuRandomized control trialsEffects of rye and whole wheat versus reﬁned cereal foods on
metabolic risk factors: A randomised controlled two-centre
intervention study
Rosalba Giacco a,*, Jenni Lappi b, Giuseppina Costabile c, Marjukka Kolehmainen b,
Ursula Schwab b,d, Rikard Landberg e, Matti Uusitupa b, Kaisa Poutanen b,f,
Giovanni Pacini g, Angela A. Rivellese c, Gabriele Riccardi a,c, Hannu Mykkänen b
a Institute of Food Science, National Research Council, Via Roma 64, 83100 Avellino, Italy
bDepartment of Clinical Nutrition, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland
cDepartment of Clinical and Experimental Medicine, School of Medicine, Federico II University, Naples, Italy
d Institute of Clinical Medicine, Internal Medicine, Kuopio University Hospital, Kuopio, Finland
eDepartment of Food Science, BioCentre, Swedish University of Agricultural Sciences, Uppsala, Sweden
fVTT Technical Research Centre of Finland, Finland
gMetabolic Unit, Institute of Biomedical Engineering, National Research Council, Padova, Italya r t i c l e i n f o
Article history:
Received 31 August 2012







Metabolic syndromeAbbreviations: ARs, alkylresorcinol homologues;
analysis; CVD, cardiovascular disease; dAIRG, dynam
response; DI, disposition index; FSIGT, frequently s
tolerance test; GI, glycaemic index; hs-CRP, high sensi
impaired fasting glucose; IGT, impaired glucose tol
receptor antagonist; IL-6, interleukin 6; OGTT, oral gl
index of fasting insulin sensitivity; SI, insulin sensitiv
crosis factor-a.
* Corresponding author. Tel.: þ39 0825 299341; fax
E-mail address: rgiacco@isa.cnr.it (R. Giacco).
0261-5614/$ e see front matter  2013 Elsevier Ltd a
http://dx.doi.org/10.1016/j.clnu.2013.01.016s u m m a r y
Background & aims: Intervention studies investigating the effects of wholegrain intake on glucose and
insulin metabolism have provided conﬂicting results. Aim of this study was the evaluation of glucose and
insulin metabolism in response to long-term consumption of rye and whole wheat compared with a diet
containing the same amount of reﬁned cereal foods, in individuals with metabolic syndrome from two
European locations (Kuopio-Finland/Naples-Italy).
Methods: 146 individuals of both genders, age range 40e65 years with metabolic syndrome, were
recruited to this study with parallel groups. After a 2e4 week run-in period, participants were assigned
to a diet based on wholegrain (wholegrain group) or on reﬁned cereal products (control group), each one
for a duration of 12 weeks. Peripheral insulin sensitivity, assessed by FSIGT, lipids and inﬂammatory
markers were measured before and at the end of intervention.
Results: 61participants in thecontrolgroupand62 in thewholegraingroupcompleted thedietary intervention.
Compliance tothe twodietswasgood.At theendof the intervention, insulin sensitivity indicesandsecretion(SI,
QUICKI, DI, dAIRG) and lipids and inﬂammatory markers did not change signiﬁcantly in the wholegrain and
control groups as compared with baseline and no differences between the two groups were observed.
Conclusions: Wholegrain cereal foods consumption compared with reﬁned cereals for 12 weeks did not
affect peripheral insulin sensitivity.
The study was registered with ClinicalTrials.gov identiﬁer NCT00945854.
 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.BIA, bioelectrical impedance
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A large body of evidence from observational studies has shown
that habitual consumption of cereal ﬁbre and wholegrain foods is
consistently associated with reduced risk of type 2 diabetes, met-
abolic syndrome and CVD.1 The protective effects of wholegrain
cereals against type 2 diabetes and CVD have been attributed to
a synergistic action of their components such as dietary ﬁbre, vi-
tamins and other molecules with antioxidant properties, phytoes-
trogens and micronutrients on several biological functions.
However, the biological mechanisms responsible for the health
effects of wholegrain are still unclear. Findings from epidemiological
studies suggest that the beneﬁts of wholegrain intake on humanutrition and Metabolism. All rights reserved.
R. Giacco et al. / Clinical Nutrition 32 (2013) 941e949942health are related to improved body weight, insulin sensitivity, lipid
metabolism, inﬂammation and antioxidant activity. Since insulin
resistance is a key factor in the pathogenesis of type 2 diabetes and
CVD, the reduced risk for type 2 diabetes and CVD observed in
wholegrain consumers could be mediated by an improvement in in-
sulin resistance. As a matter of fact, increased consumption of
wholegrain was associated with higher insulin sensitivity, lower fast-
ing insulin concentration, and lower 2-h glucose concentration after an
OGTT in many observational studies.2e5
However, so far the results of intervention studies investigating
the effects of wholegrain intake on glucose and insulin metabolism
have provided conﬂicting results. Among the clinical trials with
positiveﬁndings on insulinmetabolism, a study inhyperinsulinemic
overweight individuals showed that a 6-week period with
a wholegrain rich diet, composed of 80% wheat, reduced fasting
plasma insulin levels and improved insulin resistance as compared
with a reﬁned cereal diet6; two other studies reported that high-
ﬁbre rye bread consumption compared with reﬁned wheat bread
signiﬁcantly increased the ﬁrst phase of insulin secretion, suggest-
ing an improved beta cell function,7 reduced fasting insulin levels
and 24-h urinary C-peptide excretion.8 Other intervention studies
observedbeneﬁts ofwholegrain consumptiononplasmacholesterol
concentrations,9,10 systolic blood pressure levels,11 abdominal fat
and hs-CRP,8,12 but no effect on glucose or insulin metabolism.
Finally, some trials did not observe any effect of wholegrain con-
sumption on either insulin sensitivity ormetabolic abnormalities, or
on inﬂammatory and oxidative status.13e15 These contradictory re-
sults could be related to either different wholegrain cereals used
and/or differences in the pathophysiology of glucose metabolism in
the participants in these studies, as well as to differences in ap-
proaches used to measure glucose and insulin metabolism.16
The primary aim of our studywas to evaluate differences in glucose
and insulin metabolism, as assessed by FSIGT (frequently sampled
intravenous glucose tolerance test) in response to long-term con-
sumption of rye and wholegrain cereal products as compared with
adiet containing thesameamountof reﬁnedcereal foods, in individuals
with the metabolic syndrome. The participants were recruited in two
European locations (Kuopio, Finland and Naples, Italy) with different
assortment ofwhole-grainproducts, food culture, genetic and life-style
backgrounds. The secondary aim was to investigate the effects of this
type of diet on lipid metabolism and inﬂammatory markers.
2. Subjects and methods
2.1. Population
One hundred and forty six individuals (85 from Kuopio and 61
from Naples) of both genders, age range 40e65 years with theFig. 1. Studymetabolic syndrome, were recruited to participate in the dietary
intervention. At screening, health status and medical history of
the participants were examined by interview, clinical examination
and routine laboratory tests (glucose, lipids, haemoglobin and
liver, kidney and thyroid functions). In addition, a 75 g OGTT was
carried out to evaluate glucose tolerance and exclude those with
undiagnosed diabetes. The diagnosis of metabolic syndrome was
based on the National Cholesterol Education Program Criteria.17
Individuals were excluded if they were diagnosed with diabetes
and/or renal failure (serum creatinine > 1.5 mg/dl), liver abnor-
malities (ALT/AST ratio two times above normal values), anaemia
(Hb < 12 g/dl), any other chronic disease or if they used any drug
able to inﬂuence glucose and lipid metabolism and inﬂammation
(corticosteroid hormones other than inhaled corticosteroids,
hypolipidemic or/and anti-inﬂammatory drugs); however, in the
Kuopio study centre the use of cholesterol lowering medications
(statins) was allowed.
All participants gave their written informed consent to the study
which was approved by the Ethics Committee at the Kuopio Uni-
versity hospital and at the “Federico II” University of Naples.2.2. Study design
The studywas based on a randomized, controlled, parallel group
design and consisted of a 2e4week run-in period, duringwhich the
participants were stabilised on their own diet, and a 12-wk test
period (Fig.1). At the end of the run-in period, the participants were
randomly assigned to one of two groups: one group consumed
a diet based on wholegrain cereal products, most of them with
a low postprandial glucose and/or insulin response (wholegrain
group), and the other group consumed a diet based on reﬁned
cereal products (control group). The randomizationwas carried out
separately at each centre with stratiﬁcation for sex, age (5 years)
and BMI (25e30, 30e35 kg/m2) by use of random allocation soft-
ware. Allocation was carried out by personnel not involved in the
study; therefore the investigators and the dieticians were aware of
the group allocation of the participant only after the randomization
process had been performed. During the study, participants were
advised not to change their body weight and lifestyle habits such as
exercise and alcohol consumption and not to change their medi-
cations unless necessary.
At baseline and at 4, 8 and 12 weeks during the intervention,
participants underwent clinical investigations including measure-
ments of body weight, waist circumference and blood pressure;
fasting blood samples were taken after a 12-h overnight fast for
biochemical measurements. After the run-in and at the end of the
intervention, participants underwent FSIGT18; in addition, BIAdesign.
Table 1
Energy intake and diet composition at baseline and at the end of the intervention.
Control group (n ¼ 61) Wholegrain group (n ¼ 62)
Baseline 12-Week Baseline 12-Week
Energy (kcal/d) 1719  63a 1965  57b 1702  62 1900  57b
CHO (%) 48  0.7 49  0.6 46  0.6 48  0.6
Protein (%) 18  0.4 17.8  0.3 18  0.4 18.7  0.3c
Total fat (%) 31.8  0.6 30.8  0.7 33.5  0.6 31.0  0.7
SAFA (%) 11.0  0.3 10.9  0.3 11.4  0.3 10.2  0.3
MUFA (%) 12.1  0.3 11.9  0.3 12.9  0.3 11.1  0.3
PUFA (%) 4.9  0.2 3.9  0.2 5.3  0.2 4.8  0.2c
Cholesterol (mg/day) 228  12 225  9 238  13 207  10
Total ﬁbre (g/day) 21.6  0.8 19.8  0.7 22.7  0.8 32.6  0.7c
Cereal ﬁbre (g/day) 11.4  0.6 10.4  0.3 11.9  0.8 24.3  0.9c
a Mean  SEM (all such values).
b p < 0.02 Paired sample t test (12-week versus baseline).
c Treatment effects (Wholegrain versus Control) were evaluated by GLM where
study centre and baseline values were included as covariates, p < 0.05.
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2.3. Experimental diets
Participants were encouraged not to change their habitual meat,
dairy products, eggs, ﬁsh, fruit, vegetable and fat intake during the
study; the only difference between the wholegrain and the control
diet was the inclusion of a ﬁxed amount of wholegrain or reﬁned
cereal products as the main carbohydrate source. The wholegrain
diet in Naples was based on wholegrain products including whole
wheat bread (plus some endosperm rye bread), whole wheat pasta,
barley kernels, wholegrain oat biscuits and breakfast cereals (all
bran sticks and ﬂakes) while the control diet contained commercial
products based on reﬁned cereals such as wheat bread, rice, pizza,
cornmeal porridge, and breakfast cereals (rice krispies). The
wholegrain bread consumed by the Neapolitan participants was
90% sourdough whole wheat bread and 10% endosperm rye bread.
In Naples the average GI was 46% for the wholegrain diet and 72%
for the control diet.
In Kuopio, thewholegrain and control diets were aimed to include
20e25% of the total daily energy intake as study breads. In the
wholegrain diet, the type of bread consumed by the Kuopio
participants was 50% commercial wholegrain rye bread, 40%
endosperm rye bread, and 10% sourdough whole wheat bread. In
addition, participants in Kuopio were advised to replace their
habitual potato consumption with 210 g dry weight of whole wheat
pasta per week, and were given whole oat biscuits for snacks. In the
control group, the participants consumed commercial reﬁned wheat
breads, and only 1e2 small portions of rye products were allowed
daily.
The wholegrain products used were deﬁned as containing
a minimum of 51% wholegrain per dry substance, including the
starchy endosperm, germ, and bran, mainly in milled form.19
Commercial wholegrain rye breads were made with 100% whole-
grain ﬂour, and the endosperm rye breadwith 100% endosperm rye
ﬂour. Both the wholegrain rye bread and the endosperm rye bread
were shown to produce a low postprandial insulin response.20 The
sourdough whole wheat bread was shown to have beneﬁcial
postprandial glucose and insulin responses.21 Furthermore, both
the Finnish and Italian sourdough whole wheat breads contained
high amount of bioactive compounds present in bran like ferulic
acid, betaine, choline and alkylresocinols (data not shown).
In order to improve the adherence to the two experimental di-
ets, the test products in both diets were provided free of charge to
the participants in amounts sufﬁcient to cover their household
consumption for the whole duration of the study. For both diets
cereal products represented about 60e80% of the daily
carbohydrate intake; the remaining 20e40% of carbohydrates was
provided by fruits and vegetables according to participants’ usual
dietary habits. The intake of sugar and sugar-sweetened drinks was
minimal (<30 g/day).
The diets were controlled for energy intake to maintain body
weight of participants stable during the whole period of the
intervention.
2.4. Dietary assessment
Compliance with the experimental diets was assessed using a 4-
d food records in Kuopio and 7-d food records in Naples during the
run-in period, i.e. before starting the intervention, and at the 4th,
8th and 12th week of the intervention, to evaluate the energy
intake and the nutrient composition of the diets followed by each
participant (Fig. 1) (Table 1). Four-day food records included one
weekend day. All 4-d food records were analysed with theMICRONUTRICA program version 2.0 (Finnish Social Insurance
Institute, Turku, Finland), which utilizes a database of Finnish foods.
All 7-d food records obtained in the Italian cohort were analysed by
a computerized program using the food database of the Italian
National Institute for Foods and Nutrition. If any of the foods
recorded did not match a product already included in the database,
the nutrient values declared by the producer were added to the
database. For food whose nutrients were not declared by the pro-
ducer, the database value for the most similar product was used. In
addition to food records, the intake of test products was followed
by daily questionnaires ﬁlled in by the subjects in Kuopio and by
counting the unused test products in Naples.
The energy and nutrient composition of wholegrain and reﬁned
wheat products employed in this trial were measured directly by
the manufacturer. All participants received written and oral in-
structions given by the dietician or nutritionist concerning the diets
to follow during the intervention and were supplied with recipes
indicating how the products could be used in the best way to
ensure good adherence to the diets. Weekly or biweekly the par-
ticipants visited the clinic to collect new food products. During the
visits for the clinical and body weight measurements at 4-week
intervals, the participants returned the food records and ques-
tionnaires and were encouraged to continue on the study diet.
Plasma total AR concentration, a biomarker of wholegrainwheat
and rye intake,22 was measured at baseline and at the end of the
intervention in both groups in order to evaluate the compliance to
the experimental diets.
2.5. Blood pressure, anthropometric and body composition
measurements
Blood pressure was measured in the supine position in a stan-
dardized way after 5e10 min rest with an automatic sphygmom-
anometer. Body weight was measured on the same calibrated beam
balance scale throughout the study. Waist circumference was
measured halfway between the lowest rib and the iliac crest. Body
composition was measured by bioelectrical impedance (BIA 101S
with BODYGRAM software; Akern Srl Bioresearch, Florence, Italy).
2.6. Clinical test and laboratories analyses
Blood samples were drawn after a 12-h overnight fast, from an
antecubital vein for the measurements of plasma glucose, insulin,
lipid, and inﬂammatory markers. Peripheral insulin sensitivity was
assessed by FSIGT. A glucose dose of 300 mg/kg body weight was
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injected after 20 min. Blood samples were frequently collected for
3 h for the measurement of plasma glucose and serum insulin
concentrations, utilized to calculate the insulin sensitivity index SI
(104 min1/(mU/ml)).23,24 Insulin sensitivity at fasting was eval-
uated by the unitless QUICKI index. First-phase insulin response
was evaluated as the average insulin concentration from 2 to
10 min and expressed as dAIRG (mU/ml). The disposition index, DI,
that measures the ability of the beta cell to increase its secretion to
compensate for insulin resistance, was calculated as SI  dAIRG.25
In Naples, plasma insulin concentrations were measured by an
enzyme-linked immunosorbent assay (ELISA) for the speciﬁc
determination of biologically active insulin (DAKO Insulin, DAKO
Diagnostics, Ely, UK). Plasma glucose, cholesterol, and triglycerides
were assayed by enzymatic colourimetric methods (ABX Di-
agnostics, Montpellier, France; Roche Molecular Biochemicals,
Mannheim, Germany; Wako Chemicals GmbH, Neuss, Germany,
respectively) on a Cobas Mira autoanalyzer (ABX Diagnostics,
Montpellier, France). HDL cholesterol was isolated from plasma by
a precipitation method with a sodium phosphotungstate and
magnesium chloride solution andmeasured by the same enzymatic
colourimetric method utilized for the analysis of total cholesterol.
The LDL cholesterol concentration was calculated according to the
formula of Friedwald.
In Kuopio, serum insulinwas analysedwith a chemiluminescent
immunoassay (Advia Centaur, Siemens Medical Solution Di-
agnostics, Tarrytown, NY, USA), plasma glucosewas analysed by the
glucose hexokinase method (Konelab System Reagents; Thermo
Fisher Scientiﬁc, Vantaa, Finland), and serum total, LDL-, and HDL-
cholesterol, and triglycerides were analysed using commercial kits
(Thermo Electron, Vantaa, Finland).
The inﬂammatory markers (hs-CRP,TNF-a, IL-6, IL-1ra) were
determined in Germany at University of Ulm, in the laboratory of
Department of Internal Medicine II-Cardiology, as described by de
Mello et al.26 Measurements were done on plasma EDTA samples.
Plasma samples were analysed for AR homologues C17:0eC25:0
according to a gas chromatographyemass spectrometry-single ion
monitoring method, using molecular ions for quantiﬁcation.27
Samples were divided randomly in 17 batches and analysed in sin-
glets. In each batch, ﬁve replicates of a control samplewere included
randomly in the sequence. The within- and between-day batch
variation, determined as the coefﬁcient of variation, was <10%.
Laboratory analyses were performed blind in respect to the
assigned treatment.
2.7. Statistical analysis
The main outcome variable in the statistical analysis was insulin
sensitivity. The effects of dietary intervention on insulin sensitivity
were analysed on 111 of 123 participants completing the study. On
the basis of previous studies, a sample size of 120 individuals was
calculated to detect a 20% difference in SI between the two groups
with 0.05 signiﬁcance level and 80% power (type II error ¼ 0.1),
assuming a 15% drop-out rate.
Results for continuous variables were presented as mean 
standard error of means (mean  SEM), unless otherwise stated.
Variables with skewed distributions by ShapiroeWilks test were
normalized with logarithmic or a square root transformation and
were reported as median (interquartile range).
Energy intake and nutrient composition at baseline and during
the interventionwere calculated from the food records; the intakes
during the intervention were expressed as mean of three food re-
cords ﬁlled in at 4, 8, and 12 weeks.
A general linear model (GLM) for repeated measures was used to
evaluate differences between the groups (calculated as change of theparameter between 12-week and baseline and indicated asD) during
the intervention including the centre (Naples/Kuopio) and baseline
variables as covariates. GLM for univariate analysiswas used to assess
the difference in the relative change (calculated as the change from
baseline) of insulin sensitivity and insulin secretion indices between
the groups with the centre and baseline variables as covariates. The
effects of dietary intervention on insulin sensitivity between the
groups were also analysed in a subgroup of participants having an SI
index below the median value [<2.8  104 min1/(mU/ml)] at base-
line. A paired-samples t test was used to examine the changes com-
pared with baseline in variables within each group. For all analyses,
the level of statistical signiﬁcancewas set at p¼ 0.05 (two tails). Data
were analysed with SPSS for Windows 11.5 (SPSS Inc., Chicago, IL).
3. Results
3.1. Baseline characteristics of the participants
One hundred and twenty three participants (69 in Kuopio and
54 in Naples) completed the dietary intervention: 61 individuals
(29M/32F) in the control diet group and 62 individuals (29M/33F)
in the wholegrain diet group, while 14 individuals (18.7%) allocated
in the control group and 9 (12.6%) in the wholegrain group dropped
out because of limited time resources due to work or family-related
problems. Of the participants completing the study, 55% had IFG
and 27% had IGTat baseline. Furthermore, 92% presented highwaist
circumference, 52% low HDL cholesterol levels, 34% high fasting
plasma triglyceride levels, 65% high systolic and 57% high diastolic
blood pressure levels.
Clinical characteristics of participants are reported in Table 2. At
the baseline, the wholegrain and control groups were similar with
respect of age, body weight, BMI, waist circumference, body com-
position, blood pressure levels and fasting plasma concentrations of
glucose, insulin, lipid, and ARs. The two groupswere not different at
baseline for insulin sensitivity (SI and QUICKI) and for beta cell
function (dAIRG) (Table 3). There were no differences in fasting
plasma concentrations of the inﬂammation markers hs-CRP, IL-6,
IL-1ra, and TNF-a at baseline (Table 4).
3.2. Dietary compliance
Compliance for the wholegrain and the control diets was good.
During the intervention, both groups reported to consume the por-
tions of the breads and wholegrain and/or reﬁned cereal based
products as advised. In the wholegrain group, the mean daily intake
of the test breads in Kuopio was 185 g (of which commercial
wholegrain rye bread (mean  SD) 87  26 g, endosperm rye bread
73 21 g, and sourdoughwholewheat bread 26 4 g) and inNaples
was 153 44 g (of which sourdough whole wheat bread 139 35 g,
endosperm rye bread 14  4 g). In the control group, the mean daily
intake of reﬁned wheat breads was 197  46 g and 136  47 g in
Kuopio and Naples, respectively. In addition, in Naples the daily
consumption of whole wheat pasta was on average 85.6  22.8 g in
the wholegrain group and that of reﬁned wheat pasta plus rice plus
pizza was on average 78  19.0 g in the control group.
At baseline, the energy intake and nutrient composition of the
diets were similar between the wholegrain and the control groups
(Table 1). Comparedwith baseline, both thewholegrain and control
groups increased their energy intake (mean value of dietary records
at 4, 8 and 12 wk) during the intervention period (p ¼ 0.001).
However, the proportional nutrient composition did not change in
the control group whereas slightly higher protein and PUFA intakes
(p< 0.05) were observed in the wholegrain group (likely due to the
higher protein and PUFA content in wholegrains than in reﬁned
grains). As expected, the wholegrain group signiﬁcantly increased
Table 2
Anthropometric and fasting plasma metabolic parameters at baseline and at the end of the intervention.
Control group (n ¼ 61) Wholegrain group (n ¼ 62) p for D
Baseline 12-Week D Baseline 12-Week D
Weight (kg) 87.8  15.8a 87.8  16.1 0.03b 88.6  15.8 87.9  18.3 0.7 0.248c
BMI (kg/m2) 31.3  4.4 31.3  4.5 0.00 31.6  4.6 31.0  5.8 0.6 0.481
WC (cm) 105.8  10.7 105.8  10.8 0.04 106.7  13.0 106.4  12.8 0.3 0.621
Lean mass (kg) 56.9  12.3 56.6  12.2 0.3 56.3  11.3 55.7  11.3 0.2 0.511
Fat mass (kg) 30.9  9.8 31.2  10.3 0.3 32.3  9.3 32.2  9.4 0.06 0.375
SBP (mmHg) 135  14 130  17 5 133  15 128  15 5 0.849
DBP (mmHg) 86  8 82  9 4 84  9 81  9 3 0.526
Glucose (mmol/l) 6.06  0.56 6.00  0.61 0.06 5.89  0.56 5.94  0.56 0.05 0.310
Insulin (pmol/l) 93.1  45.1 93.1  47.2 0.001 93.8  52.8 103.5  55.6 9.72 0.074
Triglycerides (mmol/l) 1.52  0.72 1.56  0.65 0.03 1.58  1.20 1.65  0.86 0.07 0.745
Cholesterol (mmol/l) 5.28  0.93 5.31  0.90 0.03 5.15  1.09 5.25  1.14 0.10 0.417
HDL-C (mmol/l) 1.14  0.31 1.16  0.31 0.02 1.16  0.36 1.16  0.34 0.001 0.425
LDL-C (mmol/l) 3.41  0.80 3.41  0.78 0.001 3.26  0.98 3.31  0.98 0.05 0.506
Total ARs (nmol/l) 68  55 40  32d 28 75  69 122  96d þ47 0.0001
a Mean  SD (all such values).
b D ¼ change of parameter between 12-week and baseline (all such values).
c Treatment effects (Wholegrain versus Control) were evaluated by GLM with the centre and baseline variables included as covariates.
d p < 0.02 Paired sample t test (12-week versus baseline).
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compared with the control group being 12.8 and 13.8 g/day,
respectively; conversely, in the control group total and cereal ﬁbre
did not change after the intervention (Table 1).
Fasting plasma ARs concentrations increased signiﬁcantly in the
wholegrain diet group as compared with baseline and decreased in
the control diet group with a signiﬁcant difference between the two
groups at the end of the intervention (þ47 versus 28 nmol/l;
p < 0.0001,GLM analysis) (Table 2). In particular, fasting plasma ARs
concentrations increased in the wholegrain group as compared with
baseline both in Kuopio (106.4 89.3 versus 93.2 69.8 nmol/l) and
in Naples (140.2 102.0 versus 52.0 62.3 nmol/l) and decreased in
the control group both in Kuopio (36.4  26.8 versus 72.1
 52.1 nmol/l) and in Naples (43.7 38.0 versus 63.4 58.4 nmol/l).
The nutrient intake of the participants in the Kuopio (n ¼ 69)
and Naples (n ¼ 54) study centres was compared at baseline to
evaluate any differences of the background diets in the two inter-
vention sites. As compared with Kuopio, in Naples the intake of
carbohydrates (50  0.7 versus 44  0.6 E%) and monounsaturated
fatty acids (14.6  0.4 versus 10.7  0.3 E%) was higher (p < 0.05)
while the intake of proteins (17.1  0.4 versus 19.1  0.4 E%),
saturated fatty acids (9.8  0.3 versus 12.3  0.3 E%), poly-
unsaturated fatty acids (4.2  0.2 versus 5.8  0.2 E%), and cereal
ﬁbre (8.9  0.5 versus 13.8  0.7 g/day) was lower (p< 0.05). These
differences in the background diet were maintained during the
intervention (data not shown). Due to the different food cultures,
the baseline diet in Kuopio was higher in cereal ﬁbre than that in
Naples because of the habitual intake of high ﬁbre wholegrain rye
bread in Kuopio. During the intervention, in Kuopio, about 40% of
the habitual intake of wholegrain rye bread was replaced in theTable 3
Markers of insulin sensitivity and insulin secretion at baseline and at the end of the inte
Control group (n ¼ 54)a
Baseline 12 Week D (%)
SI 3.32  0.26b 3.18  0.22 4.2c (18; þ5)d
QUICKI 0.37  0.006 0.36  0.006 1.39 (2.6; 0.2)
DI 146  17 160  21 þ9.6 (14; þ24)
dAIRg (2e10 min) 54.2  5.2 55.7  5.4 þ2.8 (8.2; þ10.4)
a For 7 participants in the control group and 5 participants in the wholegrain group it w
reasons.
b Mean  SEM (all such values).
c D ¼ change of parameter between 12-week and baseline (all such values).
d 95% C.I. for D percentage (all such values).
e Treatment effects (Wholegrain versus Control) were evaluated by GLM with the cenwholegrain diet with endosperm rye bread containing less ﬁbre (7%
as comparedwith 10e14%, respectively). On the contrary, in Naples,
during the intervention the participants in the wholegrain diet
group replaced the habitual reﬁned grain consumption with
wholegrain products.
3.3. Effects of dietary intervention on anthropometric and
metabolic parameters
The mean body weight, BMI, waist circumference, fat mass and
lean fatmass and systolic and diastolic blood pressure levels did not
change during the intervention period in either group (Table 2).
Before and at the end of the intervention, BMI was 31.6 4.6 versus
31.0 5.8 kg/m2 in the wholegrain diet group and 31.3 4.4 versus
31.3  4.5 kg/m2 in the control diet group; the waist circumference
was 106.7  13.0 versus 106.4  12.8 cm in the wholegrain and
105.8  10.7 versus 105.8  10.8 cm in the control diet.
No effects of the wholegrain and control diet on fasting plasma
concentrations of glucose, insulin and lipids were observed at the
end of the intervention period (Table 2), as well as at 4 and 8 weeks
(data not shown); however, fasting plasma insulin concentrations
tended to be higher in the wholegrain group.
3.4. Effects of dietary intervention on insulin sensitivity and insulin
secretion
At the end of the intervention, SI, QUICKI, dAIRG and DI did not
change signiﬁcantly in the test and control groups as compared
with baseline; no signiﬁcant differences between the two groups
were observed at the end of the intervention period (Table 3) (datarvention.
Wholegrain group (n ¼ 57) p for D
Baseline 12 Week D (%)
2.97  0.20 3.05  0.19 þ2.7 (7.8; þ12) 0.331e
0.36  0.007 0.36  0.007 1.31 (2.6; þ0.003) 0.937
140  17 144  17 þ2.8 (16; þ15) 0.559
61.4  8.4 60.0  7.8 2.3 (15.9; þ5.1) 0.415
as not possible to perform the FSIGT either at baseline or at follow-up for technical
tre and baseline variables included as covariates.
Table 4
Concentrationsof plasma inﬂammatory markers at baseline and at the end of the intervention.
Control group (n ¼ 61) Wholegrain group (n ¼ 62) p for group effect
Median (interquartile range) Median (interquartile range)
Baseline 12-Week Baseline 12-Week
hs-CRPa (mg/dl) 1.95 (0.96; 2.56) 1.74 (1.04; 2.95) 1.95 (0.74; 4.12) 1.36 (0.62; 3.34) 0.16b
IL-6 (pg/ml) 1.41 (0.84; 2.21) 1.43 (1.07; 2.11) 1.42 (1.01; 2.32) 1.54 (1.12; 2.23) 0.52
IL-1ra (pg/ml) 251 (193; 330) 239 (190; 379) 300 (214; 518) 298 (175; 386) 0.13
TNF-a (pg/ml) 0.62 (0.43; 1.05) 0.63 (0.41; 0.90) 0.73 (0.50; 0.96) 0.68 (0.50; 0.94) 0.84
a hs-CRP data on 49 participants in the control and 52 participants in the wholegrain group, untreated with cholesterol lowering medications.
b Treatment effects (Wholegrain versus Control) on the change as D (12 week  baseline) were evaluated by GLM with the centre and baseline variables included as
covariates.
R. Giacco et al. / Clinical Nutrition 32 (2013) 941e949946were available in 54 and 57 subjects in the control and wholegrain
groups, respectively). An additional analysis was performed on
a subgroup of 54 participants (24 in the control group and 30 in the
wholegrain group) who were more insulin resistant with SI below
the median value [<2.8  104 min1/(mU/ml)] at baseline. Com-
pared with baseline, in this subgroup SI and QUICKI did not change
after the wholegrain diet (SI: 1.8  0.1 versus 2.2  0.2; QUICKI:
0.34  0.004 versus 0.34  0.004) and the control diet (SI: 1.7  0.1
versus 1.9  0.2; QUICKI: 0.34  0.004 versus 0.34  0.004); no
differences between the two groups were observed with respect to
the changes from baseline between the two intervention groups.
3.5. Effects of dietary intervention on plasma inﬂammatory
markers
Plasma concentrations of hs-CRP, IL-6, IL-1ra, and TNF-a did not
change during the intervention, and did not differ between the test
and the control group at the end of the intervention (Table 4).
Since there were some individuals at the Kuopio study centre
using cholesterol loweringmedication (n¼10 in the test and10 in the
control group), we also performed the statistical analysis after
excluding these individuals. In addition, individuals with high base-
linevalueof hs-CRP (>10mg/l) inKuopio (n¼1)and inNaples (n¼1),
both in the control group, were excluded as outliers. There was
a trend for a decreased hs-CRP concentration at the end of the
wholegrain diet [1.36 mg/dl (0.62; 3.34)] [median (interquartile
range)] as comparedwithbaseline [1.95mg/dl (0.74; 4.12)] (p¼ 0.08).
4. Discussion
Twelve weeks consumption of rye and wholegrain wheat based
diets compared with corresponding reﬁned diets did not improve
glucose and insulin metabolism nor lipid and inﬂammatory
markers in this randomised, controlled, two-centre intervention
study with Finnish and Italian individuals at risk of type 2 diabetes.
These results are in line with those of previous interventions
showing no effects of wholegrain consumption on the above
mentioned markers14,15 or on insulin sensitivity.10e12 However, the
results of the present study are at variance with the ﬁndings of
improved insulin sensitivity or ﬁrst phase insulin response
observed in association with an increased consumption of whole
wheat6 or wholegrain rye products in some studies.7,8,28 The con-
ﬂicting results on glucose and insulin metabolism in wholegrain
intervention studies may be due to differences in the methodol-
ogies used for analysing glucose and insulin metabolism or to dif-
ferences in to the amount and type of wholegrain products of
experimental diets (Appendix Table).
In this context, it is worth to underline that our study, using both
an adequate sample size and a validated methodology for insulin
sensitivity measurement, was unable to show any effect of whole-
grain on glucose and insulin metabolism. In fact, peripheral insulin
sensitivity was evaluated by FSIGT on a sample of 111 individuals,suitable to detect a clinically relevant effect (20%) of wholegrain on
insulin sensitivity with a low risk (0.1) for type II error. Any smaller
effect may lack clinical relevance. However, since the test here
employed to evaluate insulin sensitivity takes into account pre-
dominantly insulin effects at the level of muscle and adipose tissue,
it cannot be completely ruled out the possibility of beneﬁcial effects
of wholegrain consumption on glucose and insulin metabolism at
the splanchnic site and in the postprandial period.
No effects on the ﬁrst phase insulin secretion by either diet were
observed in this study using the data from FSIGT, contrary to the
study by Laaksonen et al.,28 in which insulin secretion calculated
from OGTT improved after the rye-pasta diet as compared with the
oatewheatepotato diet. However, the role of gastrointestinal hor-
mones during an OGTT should also be taken into account when
assessing the insulin response.
It is also to be considered that in our intervention the daily intake
of cerealﬁbre fromthewholegrain dietwas lower (24.30.9 g) than
that consumed in the studies of Juntunen (29.7  6.3 g)7 and
Landberg (58  7.0 g)8 which, respectively, observed beneﬁcial ef-
fects of wholegrain rye products on the acute insulin response and
on the fasting insulin and C-peptide concentrations. However, the
daily cereal ﬁbre intake in our intervention is in line with the
amount associated to a lower risk of type 2 diabetes in epidemio-
logical studies.1,29 In addition, our daily cereal ﬁbre intake, com-
pared with that very high reported in the Landberg study, is better
tolerated by consumers and more sustainable in the long term.
Moreover, in our intervention, the wholegrain diet contained
a variety of whole wheat and rye products accompanied by smaller
amounts of oat and barley. Statistical analysis performed separately
for the two centres, Kuopio and Naples, showed no difference in SI
and insulin secretion between the two intervention groups in the
participants of either centre, although in Kuopio the wholegrain
group consumed 90% of daily bread as wholegrain and endosperm
rye bread and in Naples as whole wheat bread. It is also noteworthy
that the wholegrain diet had a lower GI than the control diet in
Naples but not in Kuopio. Therefore, we could rule out that in our
experiment the absence of any beneﬁcial effect of wholegrain on
measured glucose and insulin metabolism could depend on the
type of grain (rye or wheat) and environment or culture.
In relation to the relationship betweenwholegrain consumption
and markers of subclinical inﬂammation, it is worth stressing
a reduction of plasma hs-CRP has been observed only when
wholegrain and bran rye products were consumed and that the
intake of endosperm rye bread is negatively correlated with con-
centrations of hs-CRP in plasma, as observed respectively by
Landberg et al.8 and de Mello et al.26
An additional strength in our intervention was that plasma AR
was used as a biomarker for the intake of whole wheat and rye.22
The food records showed a signiﬁcant increase in the cereal ﬁbre
intake in the wholegrain group and this was conﬁrmed by an
increase in plasma ARs concentrations, while conversely, ARs
plasma levels were decreased in the control group. These data
R. Giacco et al. / Clinical Nutrition 32 (2013) 941e949 947indicate a good adherence to the prescribed dietary treatments. The
evaluation of the AR homologues in plasma conﬁrmed a higher
consumption of rye in Kuopio as compared with a higher con-
sumption of wheat in Naples (data not shown).
Furthermore, during the intervention, participants, according to
the study design, maintained stable their body weight, body fat
composition and waist circumference that may represent con-
founding factors on insulin sensitivity and secretion.2,12,30 Our
study has many strengths but also some limitations. In fact, it does
not allow to rule out the possibility of a more relevant effect of
wholegrain on glucose and insulin metabolism in individuals with
more pronounced metabolic derangements. In addition, a more
focused evaluation of insulin sensitivity at the liver site would
probably be more appropriate to investigate the metabolic impact
of wholegrain since the effects of wholegrain are probably medi-
ated by mechanisms acting in the splanchnic region, predomi-
nantly in the postprandial period. Further limitation of the study is
the treatment durationwhich could be too short to induce relevant
modiﬁcations inmetabolic parameters which interferewith plasma
glucose and insulin regulation.
In conclusion, our randomized, well controlled two-centre
intervention clearly shows that rye or wheat based wholegrain
diets did not affect peripheral insulin sensitivity and other pa-
rameters of glucose metabolism in individuals with the metabolic
syndrome. However, it remains to be elucidated with intervention
studies of appropriate duration and sample size whether whole-
grain consumption is able to reduce the risk of type 2 diabetes or
cardiovascular diseases as suggested by observational studies.
Sources of funding
This study was supported by the European Commission in the
6th Framework Programme, Project HEALTHGRAIN (FOOD-CT-
2005-514008), by Raisio Plc Research Foundation (JL), the Nordic
Centre of Excellence projects “HELGA e wholegrains and health”
(HM, RL), “SYSDIET e Systems biology in controlled dietaryAppendix
Appendix Table





Pereira et al., 2002 6 F, 5 M hyperinsulinemic
subjects (25e56 y)
BMI 30  1 kg/m2
Randomized
crossover
2  6 wk separated












20 healthy females (3 with
IGT) (59  6 yrs)
BMI 28  3 kg/m2
Randomized
crossover
2  8 wk separated








28 M overweight subjects
(40e65 y)
BMI 30  1 kg/m2
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crossover
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22 F and 8 M subjects with
one or more abnormalities
of MetS (59  5 yrs)
BMI 28  2 kg/m2
Randomized
crossover 2  6 wk
separated by a 6
e8 wk washout
period
3 portions of bread (45 g),
2 portions of crisp bread
(12 g), 1 portion of muesli
(35 g), 1 portion of pasta
(70 g)
Planned intake of WG
ingredients ¼ 112 g
Of which 90% was
consumed by the subjects
Grains (wheat, rye, oat)
contained 50%
WG per dry substance,







Katcher et al., 2008 23 F and 24 M subjects with
MetS: WG group (45  8 y),
BMI 36  4 kg/m2
RG group (47  10 y)




Bread and rolls, ready-to-
eat cereal, brown rice,
oatmeal, pasta, salty
snacks and snack bars
(WGwas listed as the ﬁrst
ingredient on the food
label)
About 5 servings
1 serving was 1 slice of
bread, 28 g of ready-to-










Tighe et al., 2010 102 F, 104 M healthy
subjects/MetS (52  1 y)





Group 1: whole wheat
foods, 3 servings (70
e80 g wholemeal bread
and 30e40 g WG cereals)
Group 2: whole wheat
foods, 1 serving, and oats,
2 servings








17 M with prostate cancer
(73.5  4.6 y) BMI
27.5  4.6 kg/m2
Randomized
crossover 2  6
wk separated a by
2 wk washout
Wholegrain rye and rye
bran products: 247 34 g
bread, 89  17 g crisp
bread, 50  9 g breakfast
cereals, 35  10 g
porridge (uncooked)
(Fibre intake from the test




245  39 g bread,
96  19 g crisp
bread, 39  15 g
breakfast cereals,








Giacco et al., 2010 3 F, 12 M healthy subjects
(55  8 y) BMI 27 
3.0 kg/m2
Randomized
crossover 2  3
wk No washout
Wholemeal wheat bread,
pasta, rusks and crackers
(dietary cereal ﬁbre













216 healthy subjects noWG
consumer (age 46  10 yrs)




Group 1: WG 60
g/d for 16 weeks;
Group 2: WG 60
g/d for 8 weeks
followed by 120










weetabix, oat bar, WG
crisps
In all products content of
WG was >50% except rice
and pasta (Intake of WG
ingredients was 74 
28.5 g in the group 1









WG ¼ wholegrain; RG ¼ reﬁned grains; FSIGT ¼ Frequently sampled intravenous glucose tolerance test; [ improved;4 no effect; wk ¼ week. Food intake expressed as
mean  SD. MetS ¼ Metabolic Syndrome; “or absolute amount”.
a Insulin sensitivity index.
b Homeostatic model assessment.
c Quantitative insulin sensitivity check index.
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